+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation

The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation

Blood Cells, Molecules and Diseases 46(1): 19-26

GBA3, also known as cytosolic β-glucosidase, is thought to hydrolyze xenobiotic glycosides in man. Deficiency of glucocerebrosidase (GBA), a β-glucosidase degrading glucosylceramide, underlies Gaucher disease. We examined GBA3, which recently was proposed to degrade glucosylceramide and influence the clinical manifestation of Gaucher disease. Recombinant GBA3 was found to hydrolyze artificial substrates such as 4-methylumbelliferyl-β-D-glucoside and C6-NBD-glucosylceramide, but hydrolysis of naturally occurring lipids like glucosylceramide and glucosylsphingosine was hardly detected. Consistent with this, inhibition of GBA3 in cultured cells using a novel inhibitor (alpha-1-C-nonyl-DIX) did not result in an additional increase in glucosylceramide as compared to GBA inhibition alone. Examination of the GBA3 gene led to the identification of a common substitution in its open reading frame (1368T→A), resulting in a truncated GBA3 protein missing the last α-helix of its (β/α)(8) barrel. Both recombinant 1368A GBA3 and 1368A enzyme from spleen of a homozygous individual were found to be inactive. Amongst non-neuronopathic (type 1) Gaucher disease patients, we subsequently identified individuals being wild-type, heterozygous, or homozygous for the GBA3 1368T→A mutation. No correlation was observed between GBA3 1368A/T haplotypes and severity of type 1 Gaucher disease manifestation. In conclusion, GBA3 does not seem to modify type 1 Gaucher disease manifestation.

(PDF emailed within 0-6 h: $19.90)

Accession: 056280077

Download citation: RISBibTeXText

PMID: 20728381

DOI: 10.1016/j.bcmd.2010.07.009

Related references

Gaucher disease in situ molecular size of membrane bound acid beta glucosidase in type 1 type 2 and type 3 gaucher fibroblasts. Pediatric Research 20(4 PART 2): 262A, 1986

Co-Expression of NEU2 and GBA3 Causes a Drastic Reduction in Cytosolic Sialyl Free N-glycans in Human MKN45 Stomach Cancer Cells-Evidence for the Physical Interaction of NEU2 and GBA3. Biomolecules 5(3): 1499-1514, 2016

Neonatal cholestasis as initial manifestation of type 2 Gaucher disease: a continuum in the spectrum of early onset Gaucher disease. Jimd Reports 5: 95-98, 2013

Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease. Journal of Laboratory and Clinical Medicine 144(2): 65-68, 2004

In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease. Biochimica et Biophysica Acta 870(1): 76-81, 1986

Sucrose gradient analysis of phospholipid-activated beta-glucosidase in type 1 and type 2 Gaucher's disease. Archives of Biochemistry and Biophysics 238(1): 344-352, 1985

Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. Journal of Clinical Investigation 103(6): 817-823, 1999

Posttranslational processing of human lysosomal acid beta glucosidase a a continuum of defects in gaucher disease type 1 and type 2 fibroblasts. American Journal of Human Genetics 44(5): 741-750, 1989

Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients. Journal of Clinical Investigation 99(10): 2530-2537, 1997

beta-Glucosidase activities in the Norrbotten type of juvenile Gaucher's disease. Acta Neurologica Scandinavica 58(2): 89-94, 1978

Multiple deficiency of beta glucosidase activity in a case of gaucher disease type 1. Biochemical Society Transactions 9(2): 333P, 1981

Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues. Pediatric Research 14(1): 54-59, 1980

Extraosseous manifestation of Gaucher's disease type I: MR and histological appearance. European Radiology 10(10): 1660-1663, 2000